Symcel Secures €3.6M for Antibiotic Susceptibility Testing

Symcel secures €3.6 million Horizon 2020 Phase II grant for clinical validation of customized antimicrobial susceptibility testing. Multi-resistant bacterial sepsis infections to be validated utilising Symcel’s sensitive screening technology

Symcel: 21 November 2017: Symcel, the company behind the revolutionary cell-based assay tool for real-time cell metabolism measurements, calScreener™, has secured €3.572 million Horizon 2020 funding to support the company’s evaluation of improved combination testing of antibiotics against extensively drug-resistant bacteria in sepsis patients. The project runs over 28 months with a consortium of internationally recognized academic and clinical key opinion leaders from Karolinska Institutet (Stockholm, Sweden), Hospital Universitario Ramón y Cajal (Madrid, Spain), Careggi University Hospital (Florence, Italy), Rigshospitalet (Copenhagen, Denmark) and Symcel.

Antimicrobial resistance is increasing rapidly – often causing infections that are extremely difficult to treat and for which no single antibiotic has an effect. Conventional reference methods are outdated, slow and unsuitable to use against the new threat of hetero- and extensively drug-resistant (XDR) bacteria. Symcel´s screening technology will be validated as a new surrogate method to correctly and rapidly determine which antibiotics really work against multi-resistant bacteria. At the core of this problem is the unique possibility to evaluate combinations of antibiotics against XDR bacteria in the calScreener™ for synergistic effects. As WHO recently reported*, the world is running out of antibiotics – creating an immediate need for testing combinations of existing antibiotics against multi-resistant bacteria. At present, there is no clinically validated solution available, for multiple antibiotic resistance determination. calScreener™ may offer a potentially game-changing new reference method that provides the answer.

Jesper Ericsson, CEO of Symcel commented: “the spread of multi-resistant bacteria is one the most severe risks globally to human health. The world is on the cusp of a post-antibiotic era where the healthcare community faces certain harmful bacteria that are resistant to all known drugs. Consequently, little can be done to treat the critically ill patients concerned. There is a large unmet need for a technology like calScreener™ that measures the metabolism of bacteria. The only way to really be sure an antibiotic is effective in killing bacteria. The prospective clinical validation is a great opportunity for Symcel.”

Christian Giske, Deputy Head of Microbiology at Dep. of Laboratory Medicine at Karolinska Institutet and Head Physician of Bacteriology at Karolinska University Hospital, commented: “I am pleased to be part of the consortium on this exciting project. With increasing antimicrobial resistance, more individualized solutions with rapid and accurate quantitative measurements are needed as well as predicting the effects of combination therapy.”

Magnus Jansson, CSO of Symcel added: “The goal is to provide a diagnostic tool with high speed, specificity, and sensitivity in a smartly designed and packaged device with the tools available to perform multiple antibiotic susceptibility testing in a hospital setting.”

There is a large unmet need across the international healthcare community to handle and reduce antimicrobial resistance and a successful clinical validation of calScreenerTM in the Horizon 2020 project will significantly support this.


Start following SymCel on LinkedIn for our latest news

Click here for the press release in Swedish.

Click here to read the press release from Karolinska Institutet around the use of calScreener for combination testing of antibiotics.


* WHO report, Antibacterial agents in clinical development – an analysis of the antibacterial clinical development pipeline, including tuberculosis, launched today by WHO shows a severe lack of new antibiotics under development to combat the growing threat of antimicrobial resistance.

“Pharmaceutical companies and researchers must urgently focus on new antibiotics against certain types of severe infections that can kill patients in a matter of days because we have no line of defense,” says Dr. Suzanne Hill, Director of the Department of Essential Medicines at WHO.

 

Jesper Ericsson appointed new CEO of Symcel

Symcel Sverige AB today announces the appointment of Jesper Ericsson as new Chief Executive Officer – succeeding Christer Wallin who is now retiring.

1 September 2017: Symcel has today announced that Jesper Ericsson has joined Symcel as Chief Executive Officer – with the appointment effective immediately. Ericsson was formally Director of Marketing and Sales at BioLamina AB, where he was responsible for direct sales both internationally and at a global and regional distributor level. During the past 10 years, Jesper has gained broad experience of the commercialization of research-based products through his work at the Unit for Bioentrepreneurship at the Karolinska Institute, Stockholm School of Entrepreneurship and as co-founder of the Stockholm BiotechBuilders Association. He holds a PhD in neuroscience from the Karolinska Institute and a MSc in medical technology from the Royal Institute of Technology in Stockholm.

Jesper Ericsson commented: ”I very much look forward to developing the plan and globally establishing Symcel’s solutions for phenotypic screening – with a substantial focus on sales and marketing in the coming years”.

“Jesper’s experience in selling and marketing products towards the research market will strengthen Symcel’s sales within different segments, especially for microbiology applications”, remarked Björn Varnestig, Chairman of Symcel.

“The Board wishes to thank Christer Wallin for his strong commitment and contribution over the past 6 years. During this time, the company’s product CalScreener has been successfully developed and launched on the market. Christer has industrialized production processes and increased quality assurance”, Björn Varnestig added.

About Symcel Sverige AB

Symcel is a privately owned biotechnology company in Stockholm. With the product CalScreener, Symcel offers a unique cell-based tool that measures and analyzes metabolic responses of cells in real time. This robust method for phenotypic screening of cells fulfil an unmet need for cell biological research and development. The company was founded by Dr Dan Hallén and Prof. Ingemar Wadsö in 2004.

For further information, please contact:

Jesper Ericsson
CEO, Symcel Sverige AB
Phone: +46 739-80 56 86

Björn Varnestig
Chairman, Symcel Sverige AB
Phone: +46 708-38 04 59